Cibus (CBUS)
NASDAQ:CBUS
Top Page
Cibus
(NASDAQ:CBUS)
Select Model
Select Model
Rating:52Neutral
Price Target:
$3.00
▼(-18.48% Downside)
Action:ReiteratedDate:03/19/26
The score is held back primarily by weak financial performance (ongoing losses, cash burn, and reduced equity base), which raises financing and dilution risk. This is partly offset by constructive earnings-call takeaways on regulatory/commercial milestones and cost actions extending runway, while technicals are mixed (longer-term trend intact but near-term weakness) and valuation provides limited support due to negative earnings and no dividend.
Positive Factors
Regulatory Progress & Market Access
Concrete regulatory milestones across major jurisdictions materially reduce long-term market access risk for gene-edited traits. Favorable determinations and an upcoming EU plenary vote improve the odds of commercial deployments, enabling licensing and partner rollouts that support durable revenue opportunities over multiple years.
Negative Factors
Persistent Cash Burn
Continued multi-year negative cash generation requires frequent external funding and constrains strategic optionality. Ongoing negative FCF undermines internal self-financing of commercialization, heightens dilution risk, and places pressure on management to monetize partnerships quickly to achieve sustainable cash flow.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Progress & Market Access
Concrete regulatory milestones across major jurisdictions materially reduce long-term market access risk for gene-edited traits. Favorable determinations and an upcoming EU plenary vote improve the odds of commercial deployments, enabling licensing and partner rollouts that support durable revenue opportunities over multiple years.
Read all positive factors
Cibus (CBUS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$198.59M
Dividend YieldN/A
Average Volume (3M)154.04K
Price to Earnings (P/E)―
Beta (1Y)3.02
Revenue Growth-8.64%
EPS Growth85.68%
CountryUS
Employees157
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.59
Shares Outstanding69,196,120
10 Day Avg. Volume164,630
30 Day Avg. Volume154,044
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)36.47
Price to Sales (P/S)218.79
P/FCF Ratio-15.56
Enterprise Value/Market Cap1.79
Enterprise Value/Revenue97.54
Enterprise Value/Gross Profit407.97
Enterprise Value/Ebitda-5.77
Forecast
1Y Price Target
$9.50Price Target Upside158.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.16
Revenue Forecast (FY)$7.92M
Cibus Business Overview & Revenue Model
Company Description
Cibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yi...
How the Company Makes Money
null...
Cibus Earnings Call Summary
Earnings Call Date:Mar 17, 2026
(Q4-2025)
| Next Earnings Date:May 07, 2026
Earnings Call Sentiment Positive
The call conveyed substantial positive progress on technology performance, regulatory milestones, customer engagements, and near-term commercialization plans (especially for rice and sustainable ingredients). Management also executed meaningful cost reductions and secured a $22.3M financing to extend runway. Major challenges remain: the company is still loss-making with a Q4 net loss widened ~23.6%, royalty interest expense is significant, collaboration revenue timing weighed on results, and cash runway extends only into late 2026 absent further revenue or financing. Overall, the call emphasized execution and upcoming catalysts (EU plenary vote, Interox definitive agreement, Latin America field results) that support momentum but also highlighted the need to convert progress into cash flow in the near term.Positive Updates
Strong Commercial Momentum in Rice (RISE)
Seven RISE customers represent over $200 million in potential annual royalty opportunity; initial market entry targeted in Latin America in 2027, U.S. expansion in 2028, and India/Asia closer to 2030. Management is targeting 5–7 million acres in the Americas as initial scale.
Negative Updates
Widening Net Loss
Net loss was $31.9 million for the quarter ended 12/31/2025 versus $25.8 million year-ago, an increase of $6.1 million (≈23.6% higher), reflecting continuing operating losses despite cost reductions.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Commercial Momentum in Rice (RISE)
Seven RISE customers represent over $200 million in potential annual royalty opportunity; initial market entry targeted in Latin America in 2027, U.S. expansion in 2028, and India/Asia closer to 2030. Management is targeting 5–7 million acres in the Americas as initial scale.
Read all positive updates
Company Guidance
Cibus guided that it has $9.9M cash on hand (12/31/2025) and raised $22.3M gross in Jan‑2026, providing runway into late‑2026 (Q3) while targeting to cut annual net cash usage to ≈$30M or less in 2026 after ~ $10M of 2025 R&D/SG&A savings; Q4 expenses were R&D $9.4M, SG&A $5.1M, royalty interest $9.4M, and net loss $31.9M. Key commercial milestones: initial Latin America market entry targeted for 2027 (Interox LOI, definitive agreement expected late‑2026), potential U.S. expansion in 2028 and India/Asia around 2030, seven rice customers representing >$200M potential annual royalties targeting 5–7M acres in the Americas (India ≈120M acres could add ~another $200M), and a 12–15 month edit turnaround; sustainable ingredients/biofragrance commercialization and scale are expected near term (discussed a possible $20–$40M/year ramp). Regulatory catalysts highlighted include an EU NGT plenary vote expected late April 2026, UK PBO filings (submitted Jan), 17 USDA APHIS positive determinations, and favorable rulings in Ecuador and Peru.Cibus Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.64M | 4.26M | 1.82M | 157.00K | 25.99M |
| Gross Profit | -2.28M | 4.26M | 1.42M | -1.38M | -2.57M |
| EBITDA | -61.54M | -241.63M | -314.58M | -15.21M | -25.43M |
| Net Income | -127.08M | -251.39M | -267.63M | -16.89M | -29.20M |
Balance Sheet | |||||
| Total Assets | 305.05M | 350.07M | 544.41M | 22.42M | 37.19M |
| Cash, Cash Equivalents and Short-Term Investments | 9.92M | 14.43M | 32.70M | 3.43M | 13.82M |
| Total Debt | 267.96M | 36.29M | 24.62M | 13.91M | 17.88M |
| Total Liabilities | 283.22M | 252.24M | 206.12M | 15.19M | 23.06M |
| Stockholders Equity | 21.83M | 92.16M | 293.47M | 7.23M | 14.13M |
Cash Flow | |||||
| Free Cash Flow | -51.17M | -58.85M | -50.53M | -20.88M | -19.31M |
| Operating Cash Flow | -50.59M | -58.04M | -46.21M | -19.36M | -18.81M |
| Investing Cash Flow | -578.00K | -808.00K | 55.06M | -1.52M | 11.20M |
| Financing Cash Flow | 46.65M | 40.60M | 20.32M | 9.99M | 3.74M |
Cibus Technical Analysis
Positive
3.68
Price Trends
2.70
Positive
2.13
Positive
1.80
Positive
Market Momentum
-0.02
Positive
46.45
Neutral
21.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CBUS, the sentiment is Positive. The current price of 3.68 is above the 20-day moving average (MA) of 3.35, above the 50-day MA of 2.70, and above the 200-day MA of 1.80, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 46.45 is Neutral, neither overbought nor oversold. The STOCH value of 21.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CBUS.
Cibus Risk Analysis
Cibus disclosed 50 risk factors in its most recent earnings report. Cibus reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cibus Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $198.59M | -6.26 | -236.85% | ― | -8.64% | 85.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $371.86M | -2.14 | -115.27% | ― | 2925.73% | -294.29% | |
47 Neutral | $37.41M | -2.65 | -76.78% | ― | -38.81% | -76.96% | |
42 Neutral | $81.16M | -7.23 | ― | ― | ― | ― | |
41 Neutral | $27.48M | -6.26 | -88.89% | ― | 56.52% | 75.22% |
* Healthcare Sector Average
CBUS
Cibus
2.13
0.09
4.41%
CRVO
CervoMed
3.92
-4.58
-53.88%
XFOR
X4 Pharmaceuticals
4.31
-3.82
-46.99%
ABVC
ABVC BioPharma
1.06
0.26
32.50%
OKYO
OKYO Pharma Limited Sponsored ADR
1.58
0.15
10.49%
Cibus Corporate Events
Private Placements and Financing
Cibus Announces Underwritten Public Offering of Common Stock
Neutral
Jan 30, 2026
On January 29, 2026, Cibus, Inc. entered into an underwriting agreement with BTIG, LLC for an underwritten public offering of 13,333,333 shares of its Class A common stock at $1.50 per share, with company board members participating for 1,000,000 ...
Business Operations and StrategyFinancial Disclosures
Cibus streamlines operations to focus on rice traits
Positive
Jan 28, 2026
In 2025, Cibus undertook a significant operational streamlining to concentrate capital and resources on commercializing its weed management traits for rice, including a workforce reduction of about 34 employees approved in July 2025 and completed ...
Stock Buyback
Cibus executes minor internal Class A share repurchase
Neutral
Jan 6, 2026
On December 31, 2025, Cibus, Inc. repurchased 60,088 shares of its Class A common stock from employee Anthony Moran at a nominal price of $0.0001 per share, under a share purchase agreement approved by the board of directors. The transaction repre...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.